Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced a collaboration with Ciitizen, a Palo Alto based healthcare technology company that helps patients get full control of their medical records so they can find better treatment options, participate in research and find clinical trials. Praxis will utilize the Ciitizen platform to provide deeper insights across disease populations through the analysis of real-world data, initially to inform the development of PRAX-222 and PRAX-562 in SCN2A developmental and epileptic encephalopathy (SCN2A-DEE).
Search
Recent Posts
See AllIterative Scopes to Present Three Abstracts on Artificial Intelligence Applications for GI Endoscopy
Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced today that its artificial intelligence platforms will be featured in three abstract presentations at the
A study by Luna confirms pelvic floor patients prefer "in-person" to "virtual-only" for at home care
Luna, the leading provider of in-home physical therapy, has unveiled a new patient study, which casts doubt on virtual-only care for pelvic floor disorders. In the study, 97% of patients with pelvic f
TripleBlind, creator of the most complete and scalable solution for privacy enhancing computation, announces Craig Gentry as the new Chief Technology Officer. Craig will lead TripleBlind’s technology
